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Objectives of this study were to adapt a commercial human protein C (PC) colorimetric assay for use in dogs and to investigate
effects of various storage conditions. The human assay was modified by using pooled canine plasma for calibration and by
increasing the activation time. PC activity was measured in fresh canine plasma and in plasma stored under various conditions. PC
activity of some stored samples was significantly different from that of fresh plasma; however, differences were small. No difference
was detected in samples stored under similar conditions but analyzed in different laboratories using similarmethodology. Results of
this study indicate that the human colorimetric assay is suitable for canine samples if pooled canine plasma is used for calibration,
that Clinical and Laboratory Standards Institute sample storage guidelines developed for testing in humans are appropriate for
dogs, and that comparisons of results from laboratories using similar methodology are legitimate.
1. Introduction
Protein C is a vitamin K-dependent glycoprotein that is
primarily synthesized in the liver [1]. It circulates in plasma
as a zymogen of a serine protease and is activated by
thrombin-thrombomodulin complex [2]. Activated protein
C exerts antithrombotic effects by inactivating coagulation
factors Va and VIIIa; additionally, it is reported to have pro-
fibrinolytic, anti-inflammatory, and antiapoptotic properties
[2]. Many conditions are recognized to cause decreased
protein C activity in people, including liver disease, sepsis,
and inflammation [2, 3]. In dogs, protein C activity is
decreased with a variety of hepatobiliary diseases, especially
hepatic failure and congenital portosystemic shunts, and has
been used to differentiate congenital portosystemic shunts
from microvascular dysplasia secondary to portal hypoplasia
[4–6]. Protein C activity is also decreased in dogs with sepsis,
congestive heart failure, and naturally acquired food-borne
aflatoxicosis [7–10].
A canine-specific protein C assay is not commercially
available; therefore, protein C activity in dogs is measured
with human assays that employ colorimetric or clotting
principles. Several reports cite the use of pooled canine
plasma for assay calibration, instead of a commercial human
standard; these studies have been performed using various
combinations of instruments and assay reagents, including
clotting-based and colorimetric (chromogenic substrate-
based) assays [4, 6, 8, 9, 11]. Other reported variations in
methodology include different activation times, anticoagu-
lant concentrations, and centrifugation settings for separat-
ing plasma [8, 11, 12]. However, detailed descriptions of test
methodology for measuring protein C concentration in dogs
are scarce. The most detailed explanation of modification
of a human assay for dogs [11] describes a clotting-based
assay [11]. However, most studies of protein C activity in
dogs report the use of a colorimetric assay. In adapting a
commercially available human colorimetric protein C assay
(STA-Stachrom protein C colorimetric assay, Diagnostica
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Stago, Asnieres, France) for use in dogs by using canine
plasma for calibration, an apparently critical step is the
dilution of the plasma to be used as the 100% standard—
yet this information is not, to our knowledge, anywhere in
the veterinary literature. An accurate, complete description
of how this assay can be adapted for use in dogs would be
of benefit to any veterinary laboratory interested in adding a
protein C assay to its list of test offerings.
Since few veterinary laboratories currently offer protein
C assays, most veterinarians must ship samples in order
to obtain results. According to Clinical and Laboratory
Standards Institute (CLSI) guidelines [13] developed for
laboratory testing in people, samples for measurement of
human protein C activity are stable (variation < ±10%) for
24 months when frozen at −74◦C or −24◦C [13]. However,
relatively little has been published on the stability of canine
protein C under different time and temperature conditions.
One study [11] found samples to be stable for at least 1 year
at −80◦C, but the sample size was small (n = 3) and no
detailed data was reported [11]. Another study [14] found
no significant difference in results obtained using plasma
frozen at −41◦C for 12 to 24 days and those obtained using
plasma stored under similar conditions but that underwent
an additional freeze-thaw cycle; that study did not include a
fresh (unfrozen) plasma control group [14].
The objectives of this study were to adapt a commercial
human protein C colorimetric assay for use in dogs, and
then to determine the effects of various storage conditions on
results. Our hypothesis was that different storage conditions
would significantly affect results. Secondary objectives were
to compare results from our laboratory with those from
a laboratory in another state, and to establish preliminary
canine protein C reference values for our laboratory.
2. Materials and Methods
2.1. Animals. The project involved the use of 28 clinically
normal adult dogs owned by faculty, staff, or students. All
live animal work was approved in advance by an institutional
animal care and use committee (University of Tennessee,
protocol #1498). Pooled plasma was made using samples
from 15 dogs (median age = 7 years; 9 mixed breed, 6
different pure breeds; 9 spayed females, 6 neutered males).
Experimental phases 1 and 2 were done using samples from
13 dogs of varying age (phase 1, range = 3–9 years, median =
8 years; phase 2, range = 3–9 years, median = 6.5 years),
breed, and sex; samples from 2 dogs were included in both
phases.
2.2. Protein C Assay. Samples were analyzed using an auto-
mated instrument (STA Compact), and commercially avail-
able reagents (STA-Stachrom protein C colorimetric assay,
STA-Owren-Koller buffer, STA-System Controls) from the
same manufacturer (Diagnostica Stago, Asnieres, France).
The assay involves a 2-step reaction in which one reagent
(purified Agkistrodon c. contortrix venom) activates protein
C, another reagent is a chromogenic substrate for the
activated enzyme, and the intensity of the resulting color is
measured spectrophotometrically as optical density (OD).
Standard curves were established using either a commer-
cial human standard (STA-Unicalibrator, Diagnostica Stago,
Asniers, France) according to manufacturer’s instructions,
or pooled canine plasma as described below. In the regular
assay procedure, the 110% human standard calibrator is
diluted 1/3, and all test samples are automatically diluted
1/3 (personal communication, Diagnostica Stago technical
support); another veterinary laboratory using the same assay
for canine samples uses a 1/3 dilution of pooled canine
plasma as the 100% standard, and an activation time of
10 minutes instead of the default 5 minutes (personal
communication, Cornell Animal Health Diagnostic Center).
Based on this information, and on our own experience using
the human standard calibrator, we established a canine-
specific standard curve using the following dilutions of
pooled canine plasma, and a 10-minute activation time
(dilution = protein C activity): 1/3 = 100%, 1/4 = 75%,
1/6 = 50%, 1/10 = 30%, 1/20 = 15%, and pure buffer =
0%. To assess precision, two separate curves were generated
in immediate succession on the same day, both run in
duplicate. Using the second of these curves, a plasma
sample from one normal dog was chosen at random and 6
aliquots were measured as part of a single run to determine
intra-assay precision. A new canine-specific curve generated
one week later (Curve 2) was used for all subsequent
assays.
2.3. Samples Collection and Handling
2.3.1. Pooled Plasma. Blood samples (6mL) were collected
by jugular venipuncture from 15 dogs into 3.2% sodium
citrate anticoagulant (BD Vacutainer, Becton, Dickenson,
and Co., Franklin Lakes NJ). Samples were centrifuged twice
for 120 s at 13,700 g (StatSpin, StatSpin, Inc., Norwood MA),
then plasma was harvested within 30 minutes of collection,
placed in 2mL screw-cap tubes (Sarstedt, Newton NC),
frozen at −80◦C within 60 minutes of harvesting, and kept
frozen for 12 to 28 d. Samples were thawed by letting the
tubes stand at room temperature, and occasionally rolling
them between open palms. Pooled plasma was created from
250 μL aliquots of plasma free of gross lipemia or hemolysis;
any remaining plasma was refrozen at −80◦C.
Phase 1. Blood samples were collected from 9 dogs, and
plasma was harvested as described for making pooled
plasma. Each plasma sample was analyzed within 60 minutes
and the remainder was immediately frozen at −80◦C. After 4
days (n = 7) or 7 days (n = 2), the samples were thawed
and divided into 5 aliquots (0.5mL per aliquot). One of
the aliquots was analyzed immediately, and the others were
immediately refrozen under different conditions for later
testing (Table 1(a)).
Phase 2. Blood samples were collected from 6 dogs, and
plasma was harvested as described above. Each plasma
sample was divided into 5 aliquots (0.5mL per aliquot). One
of the aliquots was analyzed immediately, and the others
were immediately frozen under different conditions for later
testing (Table 1(b)).
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Table 1: Plasma storage conditions for Phase 1 (a) and Phase 2 (b).
(a)
Sample Storage conditions
Control NA (fresh plasma)
Aliquot 1.1 4 d (7 dogs) or 7 d (2 dogs) at −80◦C
Aliquot 1.2
4 d (7 dogs) or 7 d (2 dogs) at −80◦C, then
thawed, refrozen at−20◦C, and shipped with a
cold pack the next day overnight to an
independent laboratoryA; assay performed 2 d
after initial thaw from −80◦C
Aliquot 1.3
4 d (7 dogs) or 7 d (2 dogs) at −80◦C, then
thawed, refrozen at−20◦C, and packaged the next
day identically to Aliquot 1.2 (package kept at
room temperature); assay performed 2 d after
initial thaw from −80◦C
Aliquot 1.4 4 d (7 dogs) or 7 d (2 dogs) at −80
◦C, then thawed
and refrozen at −80◦C for another 4 d
Aliquot 1.5 4 d (7 dogs) or 7 d (2 dogs) at −80
◦C, then thawed
and refrozen at −80◦C for another 7 d
A
Cornell University, Animal Health Diagnostic Center.
(b)
Sample Storage conditions
Control NA (fresh plasma)
Aliquot 2.1 7 d at −80◦C
Aliquot 2.2 7 d at −20◦C
Aliquot 2.3 28 d at−80◦C
Aliquot 2.4 28 d at−20◦C
2.4. Statistical Analysis. Precision of the protein C assay
was determined by calculating coefficients of variation
(CV, defined as standard deviation/mean). Results obtained
using different types of samples (fresh v. various storage
conditions) were compared using commercial software (SAS
Version 9.2 of the SAS System for Windows, Cary, NC).
Analyses included: Pearson’s correlation, Student’s t-test for
paired comparisons, and repeated measures ANOVA with
Shapiro-Wilk test for normality of residuals and Levene’s
F-test for equal variances. A P-value < .05 was consid-
ered significant. For the null hypothesis that there were
no differences between control samples and treatments, a
Bonferroni correction was employed to adjust for multiple
t-tests (for Phase 1 comparisons, α/n = 0.05/5 = 0.01;
for Phase 2 comparisons, α/n = 0.05/4 = 0.0125). For
the null hypothesis that there were no differences between
treatments, Tukey’s post-hoc method was used to adjust
for multiple comparisons. Preliminary canine protein C
reference values for our laboratory were based on minimum
and maximum values from the combined control sample
data sets of Phase 1 and Phase 2.
3. Results and Discussion
3.1. Protein C Assay. Based on 4 data points per dilution
(2 standard curves, both run in duplicate), the CVs of
OD measurements were < 5% (low CV = 2.0%, high
CV = 4.8%) for each dilution except pure buffer; for pure
Table 2: Comparison of standard curves generated 1 week apart,
using pooled canine plasma (Curves 1 and 2), and a curve generated
using the manufacturer’s standard protocol (Mfr Std). Results for
protein C (PC) activity shown here are hypothetical, calculated by
inserting arbitrary optical density (OD) values into the regression
equations for the curves (Curve 1: c = [1278.276 × d] − 12.397;
Curve 2: c = [1257.324 × d] − 9.60; Mfr Std curve: c = [515.734 ×
d] − 0.608; where c = PC activity and d = OD). Actual instrument
output for Curve 2 is shown in Figure 1.
Protein C activity (%)
OD Curve 1 Curve 2 Mfr Std curve
0.02 13 16 10
0.04 39 41 20
0.06 64 66 30
0.08 90 91 41
0.10 115 116 51
0.12 141 141 61
























Figure 1: Instrument output for Curve 2. The standard curve was
established using the following dilutions of pooled canine plasma
(dilution = protein C activity): 1/3 = 100%, 1/4 = 75%, 1/6 = 50%,
1/10 = 30%, 1/20 = 15%, and pure buffer = 0%.
buffer, 3 readings were 0.000 and 1 was 0.001. Based on 6
separate measurements of the same sample as part of a single
assay run, the CV was 1.4%. Standard curves generated 1
week apart were very similar (Table 2); the instrument
output for the second of these curves is shown in Figure 1.
Protein C activity values were consistently much lower using
the commercial human standard instead of pooled canine
plasma to calibrate the assay (data not shown).
Phase 1. Phase 1 results are summarized in Table 3(a).
Correlation for comparisons of fresh samples with
samples stored under the 5 different conditions ranged from
r = 0.76 to r = 0.93. Correlations for comparisons of one
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Table 3: Protein C activity results of fresh (control) and stored plasma for Phase 1 (a) and Phase 2 (b). Cross symbols indicate results of
comparisons of control and treatment groups, and alphabetical symbols indicate results of comparisons of different treatment groups; results
for groups including the same symbols are not significantly different.
(a) Protein C Activity (%, mean ± SD).
Control 4–7 d, −80◦C 4–7 d, −80
◦C; thawed,
2 d, −20◦C, send-out
4–7 d, −80◦C; thawed,
2 d, −20◦C, in-house
4–7 d, −80◦C;
thawed, 4 d, −80◦C
4–7 d, −80◦C;
thawed, 7 d, −80◦C
95 ± 10† 100 ± 15†, a, b, c 97 ± 14†, b 102 ± 11†, a, b, c 111 ± 16‡, c 105 ± 15‡, a, b, c
(b) Protein C Activity (%, mean ± SD).
Control 7 d, −80◦C 7 d, −20◦C 28 d, −80◦C 28 d, −20◦C
94 ± 12† 94 ± 11†, a 97 ± 11‡, a 88 ± 10‡, b 87 ± 10‡, b
storage condition with other storage conditions ranged from
r = 0.77 to r = 0.98.
Samples stored for 4 to 7 d at −80◦C, then thawed and
refrozen at −80◦C for either an additional 4 d or 7 d, had
significantly higher protein C activity than control samples.
Samples frozen for 4 to 7 d at −80◦C, then thawed and
refrozen at −20◦C for an additional 2 d and measured in-
house, had higher protein C activity than control samples;
this difference was marginally significant (P < .02).
There was no significant difference in results determined
by two different laboratories using samples stored under the
same conditions (4 to 7 d at−80◦C, then thawed and refrozen
at −20◦C for an additional 2 d). Samples stored for 4 to
7 d at −80◦C, then thawed and refrozen at −20◦C for an
additional 2 d and measured by a laboratory in another state,
had significantly lower protein C activity than samples stored
for 4 to 7 d at −80◦C, then thawed and refrozen at −80◦C for
an additional 4 d. Samples stored for 4 to 7 d at −80◦C had
lower protein C activity than samples stored for 4 to 7 d at
−80◦C, then thawed and refrozen at −80◦C for an additional
4 d; this difference was marginally significant (P = .0503).
Phase 2. Phase 2 results are summarized in Table 3(b).
Correlation was high (r > .95) for all comparisons of
fresh samples with samples stored under various conditions,
and for all comparisons of one storage condition with other
storage conditions.
Samples stored for 7 d at −20◦C had significantly higher
protein C activity, and samples stored for 28 d at either
temperature (−20◦C or −80◦C) had significantly lower
protein C activity, than control samples.
Samples stored for 7 d had significantly higher protein C
activity than samples stored for 28 d, irrespective of storage
temperature.
3.2. Preliminary Reference Values. Based on the combined
control sample data sets of Phase 1 and Phase 2, the
minimum and maximum values for protein C activity
were 80% and 115%, respectively. We are using these as
preliminary lower and upper reference limits, respectively, in
our laboratory.
3.3. Discussion. This study was motivated by our desire to
measure canine protein C activity in our laboratory, and
to learn more about effects of different storage conditions
on test results. Limitations of the study included relatively
small sample sizes and fragmentation into two experimental
phases to investigate storage effects. Despite these limitations,
we expect this report to be useful to anyone interested in
establishing a canine protein C assay in their own laboratory
or seeking more information about effects of different
storage conditions (including shipping samples to another
institution for analysis).
In our laboratory, the human standard for assay cali-
bration had unacceptably low results (Table 2), similar to
what has been reported by others [11]. This phenomenon
may occur because the protein C-activating reagent, a
highly purified extract of the venom of the Agkistrodon
c. contortrix snake, does not work as effectively on the
canine protein. Investigators evaluating effects of a similar
extract using a clotting-based assay found canine samples
to be markedly hyporesponsive compared to samples from
humans, cattle, and horses [15]; the precise reason for this
diminished effect is not clear, but the canine protein C
is only partially homologous (72%) with the human form
[15]. Nevertheless, our findings and those of others indicate
that Agkistrodon c. contortrix venom works sufficiently on
canine samples to enable the measurement of protein C
activity if pooled canine plasma is used to calibrate the assay.
Using this approach, our preliminary reference values of 80–
115%, based on minimum and maximum values because
of the relatively small sample size, are consistent with those
reported by Toulza et al. (75–135%) [4] and Bauer et al. (76–
119%) [4, 11]. The precision of the assay was acceptable: our
coefficients of variation were lower than reported by others
[4, 8, 11] and met the performance goals for diagnostic
application in humans [4, 8, 11, 16].
We investigated effects of storage conditions different
from those previously reported. In one previous study,
plasma samples were stored at−20◦C for 2 months or−60◦C
for 10 months before analysis [15]. In another study, samples
were stored for a maximum of 3 weeks at −80◦C, although
the analysis of aliquots of 3 specimens also stored for 13
months at −80◦C found no change in results [11]. In a
third study, canine plasma was stored up to 2 months at
−70◦C before batches of samples were shipped to an outside
laboratory for analysis [8]. We used conventional statistical
methods to test for significant differences in protein C
activity. Other investigators [17, 18] have defined stability
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of the analyte as a change of <±10% from the initial value
[17, 18]. Using either approach to our data, the protein
C activity of some stored samples was different from that
of fresh plasma. In addition, some differences were not
statistically significant but had low P-values, suggesting
that the lack of significance could be due to small sample
size. However, the mean values for all treatment groups
were within the reference limits and the differences, even
when statistically significant, were small; moreover, only
samples that underwent two freeze-thaw cycles exceeded
10% variation, and then only marginally.
Based on these findings, we interpret the differences in
results after the experimental storage conditions to be of little
to no clinical significance. This interpretation is consistent
with the findings of investigators who have studied the
effects of different storage conditions on human or canine
protein C activity [11, 14, 17–20]. Clinical and Laboratory
Standards Institute guidelines [13] developed for laboratory
testing in people indicate that specimens for protein C testing
should be kept at room temperature and centrifuged and
tested within 4 h from time of collection, or, if testing is not
completed within 4 hours, platelet-poor plasma should be
frozen at −20◦C for up to 2 weeks or at −70◦C for long-
term storage [13]. Based on our results and those of others,
we believe the CLSI sample storage guidelines developed
for testing in humans are also appropriate for testing in
dogs. The CLSI guidelines do not include any specific
recommendations regarding effects of repeated freeze-thaw
cycles on protein C activity. Our recommendation is to avoid
repeated freeze-thaw cycles, unless future work addressing
this issue more definitively indicates otherwise.
Protein C activity was not significantly different in
samples stored under similar conditions but analyzed in
different laboratories. The two laboratories in this study
used the same instruments and assays but different batches
of pooled canine plasma to calibrate the assay. The lack
of significant difference suggests that data generated from
laboratories using essentially the same methodology can be
legitimately compared. Variability in protein C results within
and between laboratories has been the subject of study in
human laboratories but, to our knowledge, not in veterinary
laboratories [21].
4. Conclusions
In summary, this report describes how we adapted a com-
mercial human colorimetric protein C assay for use in dogs.
Our preliminary reference values are consistent with those
of other investigators using colorimetric or clotting-based
assays, and the precision of the assay compared favorably
with other reports and with performance goals established
for human laboratories. In addition, we report the effects
of previously unreported storage conditions on test results.
We believe that the differences between fresh samples and
those stored under the study conditions were of little to
no clinical significance, that CLSI guidelines developed for
testing in humans are also appropriate for dogs, and that
comparisons of results from laboratories using essentially the
same methodology are likely to be valid.
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